Search Results - "Leeuwen, Roelof W.F."

The administration of immune checkpoint inhibitors via an elastomeric pump versus conventional intravenous infusion: an economic perspective by Zietse, Michiel, Malmberg, Ruben, van Leeuwen, Roelof W F, Thielen, Frederick W, Uyl-de Groot, Carin A

“…Recent studies have underscored the potential of innovative administration methods to mitigate the capacity burden on healthcare systems, without compromising…”
Get full text

Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study by Man, Femke M., Hussaarts, Koen G.A.M., With, Mirjam, Oomen‐de Hoop, Esther, Bruijn, Peter, Halteren, Henk K., Burg‐de Graauw, Nicole C.H.P., Eskens, Ferry A.L.M., Gelder, Teun, Leeuwen, Roelof W.F., Mathijssen, Ron H.J.

“…Regorafenib exposure could potentially be influenced by an interaction with acid‐reducing drugs. In this crossover trial, patients were randomized into two…”
Get full text

Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules by Zhou, Guoying, Sprengers, Dave, Mancham, Shanta, Erkens, Remco, Boor, Patrick P.C., van Beek, Adriaan A., Doukas, Michail, Noordam, Lisanne, Campos Carrascosa, Lucia, de Ruiter, Valeska, van Leeuwen, Roelof W.F., Polak, Wojciech G., de Jonge, Jeroen, Groot Koerkamp, Bas, van Rosmalen, Belle, van Gulik, Thomas M., Verheij, Joanne, IJzermans, Jan N.M., Bruno, Marco J., Kwekkeboom, Jaap

“…[Display omitted] •NK cells and cytotoxic T cells infiltrate poorly into cholangiocarcinoma.•Regulatory T cells accumulate in cholangiocarcinoma.•PD1, CTLA4…”
Get full text

Potential drug interactions and duplicate prescriptions among ambulatory cancer patients: a prevalence study using an advanced screening method by van Leeuwen, Roelof W F, Swart, Eleonora L, Boom, Frits A, Schuitenmaker, Martin S, Hugtenburg, Jacqueline G

“…The pharmacotherapeutic treatment of patients with cancer is generally associated with multiple side-effects. Drug interactions and duplicate prescriptions…”
Get full text

Effect of alternative dosing strategies on sustainable healthcare: A carbon footprint analysis of nivolumab and pembrolizumab treatment in the Netherlands by Malmberg, Ruben, Loosveld, Jurrien, Schilte, Hans-Peter, van Leeuwen, Roelof W.F., Burdorf, Alex

“…e13564 Background: Hospitals contribute significantly to greenhouse gas (GHG) emissions and face a moral obligation to prioritize reduction of GHG emissions…”
Get full text

Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective by van Leeuwen, Roelof W F, PharmD, van Gelder, Teun, Prof, Mathijssen, Ron H J, Prof, Jansman, Frank G A, Dr

“…Summary In the past decade, many tyrosine-kinase inhibitors have been introduced in oncology and haemato-oncology. Because this new class of drugs is…”
Get full text

Greening Ireland’s oncology practice: Reducing climate toxicity and improving sustainability in a national chemotherapy formulary by Lynch, Emer, Bredin, Philip Hugh, Weadick, Catherine, Barry, Simon L, Dorney, Niamh, Hamid, Munzir, Hennessy, Maeve, Myo Oo, Nay, Bryan, Alex J., Cooke, Katie, O'Mahony, Deirdre, van Leeuwen, Roelof W.F., Van De Poll, Matthijs, Collins, Dearbhaile Catherine, O'Reilly, Seamus

“…e13557 Background: Climate change has been acknowledged by the World Health Organisation (WHO) as a “fundamental threat” to healthcare delivery. However,…”
Get full text

Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer by van Leeuwen, Roelof W F, Peric, Robert, Hussaarts, Koen G A M, Kienhuis, Emma, IJzerman, Nikki S, de Bruijn, Peter, van der Leest, Cor, Codrington, Henk, Kloover, Jeroen S, van der Holt, Bronno, Aerts, Joachim G, van Gelder, Teun, Mathijssen, Ron H J

“…Erlotinib depends on stomach pH for its bioavailability. When erlotinib is taken concurrently with a proton pump inhibitor (PPI), stomach pH increases, which…”
Get full text

Clinical implications of food–drug interactions with small-molecule kinase inhibitors by Veerman, G D Marijn, Hussaarts, Koen G A M, Jansman, Frank G A, Koolen, Stijn W L, van Leeuwen, Roelof W F, Mathijssen, Ron H J

“…During the past two decades, small-molecule kinase inhibitors have proven to be valuable in the treatment of solid and haematological tumours. However, because…”
Get full text

Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab by Malmberg, Ruben, Zietse, Michiel, Dumoulin, Daphne W, Hendrikx, Jeroen J M A, Aerts, Joachim G J V, van der Veldt, Astrid A M, Koch, Birgit C P, Sleijfer, Stefan, van Leeuwen, Roelof W F

“…Immune checkpoint inhibitors have revolutionised cancer treatment by offering durable responses to many patients with solid and haematological cancers. The…”
Get full text

Evidence- and consensus-based guidelines for drug-drug interactions with anticancer drugs; A practical and universal tool for management by van Leeuwen, Roelof W.F., le Comte, Marianne, Reyners, Anna K.L., van den Tweel, Annemieke, van Vlijmen, Bas, Kwee, Wilma, Wensveen, Brigit, Steeghs, Neeltje, Visser, Otto, van Gelder, Teun, Jansman, Frank G.A.

“…Drug-drug interactions (DDIs) with anticancer drugs are common and can significantly affect efficacy and toxicity of treatment. Therefore, a Dutch…”
Get full text

Drug–drug interactions in patients treated for cancer: a prospective study on clinical interventions by van Leeuwen, R.W.F., Jansman, F.G.A., van den Bemt, P.M.L.A., de Man, F., Piran, F., Vincenten, I., Jager, A., Rijneveld, A.W., Brugma, J.D., Mathijssen, R.H.J., van Gelder, T.

“…Drug interactions are of major concern, since cancer patients take many medications and may have serious consequences. Therefore, a study was designed to…”
Get full text

Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options by van Leeuwen, Roelof W. F., Jansman, Frank G. A., Hunfeld, Nicole G., Peric, Robert, Reyners, Anna K. L., Imholz, Alex L. T., Brouwers, Jacobus R. B. J., Aerts, Joachim G., van Gelder, Teun, Mathijssen, Ron H. J.

“…Tyrosine kinase inhibitors (TKIs) have rapidly become an established factor in oncology, and have been shown to be effective in a wide variety of solid and…”
Get full text

Letter to the editor: Comments on ‘A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation’ by Diekstra, Meta H.M., Malmberg, Ruben, Sleijfer, Stefan, van Leeuwen, Roelof W.F.

Get full text

The added value of H2 antagonists in premedication regimens during paclitaxel treatment by Cox, Juul M., van Doorn, Leni, Malmberg, Ruben, Oomen-de Hoop, Esther, Bosch, Tessa M., van den Bemt, Patricia M. L. A., Boere, Ingrid A., Jager, Agnes, Mathijssen, Ron H. J., van Leeuwen, Roelof W. F.

“…Background Ranitidine, a histamine 2 blocker, is the standard of care to prevent hypersensitivity reactions (HSRs) caused by paclitaxel infusion. However, the…”
Get full text

Clinically relevant drug interactions with multikinase inhibitors: a review by Hussaarts, Koen G. A. M., Veerman, G. D. Marijn, Jansman, Frank G. A., van Gelder, Teun, Mathijssen, Ron H. J., van Leeuwen, Roelof W. F.

“…Multikinase inhibitors (MKIs), including the tyrosine kinase inhibitors (TKIs), have rapidly become an established factor in daily (hemato)-oncology practice…”
Get full text

Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen by Braal, C. Louwrens, Hussaarts, Koen G. A. M., Seuren, Lieke, Oomen-de Hoop, Esther, de Bruijn, Peter, Buck, Stefan A. J., Bos, Monique E. M. M., Thijs-Visser, Martine F., Zuetenhorst, Hanneke J. M., Mathijssen-van Stein, Daniëlle, Vastbinder, Mijntje B., van Leeuwen, Roelof W. F., van Gelder, Teun, Koolen, Stijn L. W., Jager, Agnes, Mathijssen, Ron H. J.

“…Background Many cancer patients use additional herbs or supplements in combination with their anti-cancer therapy. Green tea—active ingredient…”
Get full text

Influence of Cow’s Milk and Esomeprazole on the Absorption of Erlotinib: A Randomized, Crossover Pharmacokinetic Study in Lung Cancer Patients by Veerman, G. D. Marijn, Hussaarts, Koen G. A. M., Peric, Robert, Oomen-de Hoop, Esther, Landa, Kersten D., van der Leest, Cor H., Broerse, Suzanna D., Rutten, Hugo B., Belderbos, Huub N. A., Steendam, Christi M. J., Paats, Marthe S., Koolen, Stijn L. W., Dingemans, Anne-Marie C., van Gelder, Teun, van Leeuwen, Roelof W. F., Aerts, Joachim G. J. V., Mathijssen, Ron H. J.

“…Introduction Erlotinib’s gastrointestinal solubility and absorption are decreased by proton pump inhibitors (PPIs). Since erlotinib is a lipophilic drug, we…”
Get full text

The Risk of QTc-Interval Prolongation in Breast Cancer Patients Treated with Tamoxifen in Combination with Serotonin Reuptake Inhibitors by Hussaarts, Koen G. A. M., Berger, Florine A., Binkhorst, Lisette, Oomen - de Hoop, Esther, van Leeuwen, Roelof W. F., van Alphen, Robbert J., Mathijssen - van Stein, Daniëlle, de Groot, Natasja M. S., Mathijssen, Ron H. J., van Gelder, Teun

“…Purpose Antidepressants like the serotonin reuptake inhibitors (SRIs) are often used concomitantly with tamoxifen (e.g. for treatment of depression). This may…”
Get full text

Influence of Enzalutamide on Cabazitaxel Pharmacokinetics: a Drug-Drug Interaction Study in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients by Belderbos, Bodine P S, Bins, Sander, van Leeuwen, Roelof W F, Oomen-de Hoop, Esther, van der Meer, Nelly, de Bruijn, Peter, Hamberg, Paul, Overkleeft, Esther N M, van der Deure, Wendy M, Lolkema, Martijn P, de Wit, Ronald, Mathijssen, Ron H J

“…In ongoing clinical research on metastatic castration-resistant prostate cancer (mCRPC) treatment, the potential enhanced efficacy of the combination of…”
Get full text